About this episode

This episode discusses the differences between MASH and MASLD and their implications for diabetes management.

What is the difference between MASH and MASLD? In this special episode, Dr. Neil Skolnik breaks down these conditions, which affect insulin resistance of the liver, an area of increasing concern for people with diabetes. This special episode is sponsored with support from Lilly . Presented by: Neil Skolnik , MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jay Shubrook , DO, Professor and Diabetologist in the Department of Clinical Sciences and Community Health At Touro University California College of Osteopathic Medicine Susan Kuchera , MD, Program Director of the Jefferson Health Abington Family MedicineResidency Program and Associate Clinical Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University. References: Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease . Gastroenterology, 2026; 171, 164-183 Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need…

People in this episode

Host: Neil Skolnik

Guests: Jay Shubrook, Susan Kuchera

Topics covered

• Metabolic Dysfunction
• Liver Disease
• Diabetes
• Insulin Resistance
• Health Education

Keywords

• MASH
• MASLD
• insulin resistance
• liver disease
• diabetes
• healthcare

Sponsors

Lilly

Mentioned in this episode

Organizations: American Diabetes Association

Books & works: Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease, Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention, A Clinical Update on MASLD

More episodes of DOC Updates

• Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone · September 8, 2026 · 40 min
• Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance · August 24, 2026 · 32 min
• Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D · August 17, 2026 · 33 min
• Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more! · August 10, 2026 · 36 min
• Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more! · August 10, 2026 · 32 min
• Special Edition: Hypertension Part I—Overview and Management · August 6, 2026 · 34 min

Explore listener stats, chart rankings, contacts and more on the DOC Updates podcast page.